Novel therapeutic candidate targets key driver of HCC in genomically defined subset of patients

24 abril 2015

Findings on a novel therapeutic candidate for a genomically defined subset of hepatocellular carcinoma (HCC) patients with an aberrant fibroblast growth factor receptor 4 (FGFR4) pathway have been presented. BLU-554, a small molecule inhibitor of FGFR4, has been identified as a potential treatment option for up to 30 percent of HCC patients.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/HRSnBqPakfI/150424085702.htm

Volver